Sensei Biotherapeutics (NASDAQ:FTH) Rating Increased to Strong-Buy at Robert W. Baird

Robert W. Baird upgraded shares of Sensei Biotherapeutics (NASDAQ:FTH) to a strong-buy rating in a research note issued to investors on Thursday morning,Zacks.com reports.

A number of other brokerages have also weighed in on FTH. Weiss Ratings initiated coverage on Sensei Biotherapeutics in a report on Wednesday, June 17th. They issued a “sell (d-)” rating on the stock. HC Wainwright started coverage on shares of Sensei Biotherapeutics in a report on Monday, June 22nd. They set a “buy” rating and a $60.00 target price for the company. Finally, BTIG Research upgraded shares of Sensei Biotherapeutics to a “strong-buy” rating in a research report on Thursday, June 11th. Two research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Sensei Biotherapeutics has a consensus rating of “Buy” and an average target price of $58.50.

Sensei Biotherapeutics Price Performance

Shares of FTH opened at $22.87 on Thursday. Sensei Biotherapeutics has a one year low of $6.32 and a one year high of $36.76. The company has a market cap of $30.69 million, a P/E ratio of -0.16 and a beta of -0.25.

Insider Activity at Sensei Biotherapeutics

In related news, CEO Anand Kiran Parikh acquired 2,806 shares of the stock in a transaction on Monday, June 22nd. The shares were bought at an average price of $19.76 per share, with a total value of $55,446.56. Following the completion of the purchase, the chief executive officer owned 764,234 shares of the company’s stock, valued at approximately $15,101,263.84. This represents a 0.37% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Brian C. Stephenson bought 6,250 shares of the company’s stock in a transaction on Friday, June 26th. The stock was bought at an average price of $24.95 per share, with a total value of $155,937.50. Following the completion of the acquisition, the chief financial officer owned 33,054 shares in the company, valued at $824,697.30. This represents a 23.32% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders purchased 35,860 shares of company stock valued at $862,703. Insiders own 7.00% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.